An Exosome-Based Liquid Biopsy Shows Promise for Early Detection of Pancreatic Cancer

An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at theAmerican Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10 in San Diego. “Pancreatic cancer is one of the most fatal malignancies, in large part because the majority of patients are diagnosed only after the cancer has already metastasized,” said Ajay Goel, PhD, senior author of the study and the Chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope.

Login Or Register To Read Full Story